{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:51:44Z","timestamp":1792443104922,"version":"4.5.0"},"reference-count":98,"publisher":"American Medical Association (AMA)","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2020,10,27]]},"DOI":"10.1001\/jama.2020.17025","type":"journal-article","created":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T15:07:12Z","timestamp":1602688032000},"page":"1651","source":"Crossref","is-referenced-by-count":416,"title":["Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults"],"prefix":"10.1001","volume":"324","author":[{"given":"Michael S.","family":"Saag","sequence":"first","affiliation":[{"name":"University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh T.","family":"Gandhi","sequence":"additional","affiliation":[{"name":"Harvard Medical School and Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer F.","family":"Hoy","sequence":"additional","affiliation":[{"name":"Monash University and Alfred Hospital, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael J.","family":"Landovitz","sequence":"additional","affiliation":[{"name":"University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie A.","family":"Thompson","sequence":"additional","affiliation":[{"name":"AIDS Research Consortium of Atlanta, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul E.","family":"Sax","sequence":"additional","affiliation":[{"name":"Harvard Medical School and Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davey M.","family":"Smith","sequence":"additional","affiliation":[{"name":"University of California, San Diego, La Jolla"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance A.","family":"Benson","sequence":"additional","affiliation":[{"name":"University of California, San Diego, La Jolla"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan P.","family":"Buchbinder","sequence":"additional","affiliation":[{"name":"San Francisco Department of Public Health and University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"del Rio","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Joseph J.","family":"Eron","sequence":"additional","affiliation":[{"name":"School of Medicine, University of North Carolina, Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"F\u00e4tkenheuer","sequence":"additional","affiliation":[{"name":"University Hospital Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huldrych F.","family":"G\u00fcnthard","sequence":"additional","affiliation":[{"name":"University Hospital Zurich and Institute of Medical Virology, University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Molina","sequence":"additional","affiliation":[{"name":"University of Paris and Saint-Louis\/Lariboisi\u00e8re Hospitals, APHP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna M.","family":"Jacobsen","sequence":"additional","affiliation":[{"name":"International Antiviral Society\u2013USA, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Volberding","sequence":"additional","affiliation":[{"name":"University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"jsc200004r1","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1001\/jama.2018.8431","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society\u2013USA panel.","volume":"320","author":"Saag","year":"2018","journal-title":"JAMA"},{"issue":"9","key":"jsc200004r2","first-page":"1193","article-title":"The periodic health examination.","volume":"121","author":"Canadian Task Force on the Periodic Health Examination","year":"1979","journal-title":"Can Med Assoc J"},{"key":"jsc200004r3","article-title":"Rapid initiation of antiretroviral therapy for people living with HIV.","volume":"6","author":"Mateo-Urdiales","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"jsc200004r4","article-title":"Engagement in care, viral suppression, drug resistance and reasons for non-engagement after home-based same-day ART initiation in Lesotho: a two-year follow-up of the CASCADE trial.","author":"Amstutz","journal-title":"Clin Infec Dis"},{"issue":"5","key":"jsc200004r5","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1097\/QAD.0000000000002124","article-title":"RAPID antiretroviral therapy: high virologic suppression rates with immediate antiretroviral therapy initiation in a vulnerable urban clinic population.","volume":"33","author":"Coffey","year":"2019","journal-title":"AIDS"},{"issue":"1","key":"jsc200004r6","first-page":"407","article-title":"Rapid start lead to sustained viral suppression in young people in the South [Abstract 1073] in special issue: Abstracts From the 2020 Conference on Retroviruses and Opportunistic Infections.","volume":"28","author":"Seybolt","year":"2020","journal-title":"Top Antivir Med"},{"issue":"9","key":"jsc200004r7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0222067","article-title":"Too fast to stay on track? shorter time to first anti-retroviral regimen is not associated with better retention in care in the French Dat\u2019AIDS cohort.","volume":"14","author":"Cuzin","year":"2019","journal-title":"PLoS One"},{"issue":"6","key":"jsc200004r8","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy104","article-title":"Implementation of a rapid entry program decreases time to viral suppression among vulnerable persons living with HIV in the Southern United States.","volume":"5","author":"Colasanti","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"10167","key":"jsc200004r10","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","article-title":"Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.","volume":"393","author":"Cahn","year":"2019","journal-title":"Lancet"},{"issue":"9","key":"jsc200004r11","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1056\/NEJMoa1905230","article-title":"Neural-tube defects and antiretroviral treatment regimens in Botswana.","volume":"381","author":"Zash","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"jsc200004r13","first-page":"42","article-title":"Safety and efficacy of DTG vs EFV and TDF vs TAF in pregnancy: IMPAACT 2010 trial [Abstract 130] in special issue: Abstracts From the 2020 Conference on Retroviruses and Opportunistic Infections.","volume":"28","author":"Chinula","year":"2020","journal-title":"Top Antivir Med"},{"issue":"8","key":"jsc200004r14","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1093\/jac\/dky145","article-title":"Obesity following ART initiation is common and influenced by both traditional and HIV-\/ART-specific risk factors.","volume":"73","author":"Bakal","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"jsc200004r15","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1089\/jwh.2017.6717","article-title":"HIV-infected women gain more weight than HIV-infected men following the initiation of antiretroviral therapy.","volume":"27","author":"Bares","year":"2018","journal-title":"J Womens Health (Larchmt)"},{"issue":"6","key":"jsc200004r16","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1093\/cid\/ciz999","article-title":"Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials.","volume":"71","author":"Sax","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"9","key":"jsc200004r17","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1056\/NEJMoa1904340","article-title":"Dolutegravir-based or low-dose efavirenz-based regimen for the treatment of HIV-1.","volume":"381","author":"Kouanfack","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"jsc200004r18","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1056\/NEJMoa1902824","article-title":"Dolutegravir plus two different prodrugs of tenofovir to treat HIV.","volume":"381","author":"Venter","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"jsc200004r19","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy201","article-title":"Changes in waist circumference in HIV-infected individuals initiating a raltegravir or protease inhibitor regimen: effects of sex and race.","volume":"5","author":"Bhagwat","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"10246","key":"jsc200004r20","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0140-6736(20)31065-5","article-title":"Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.","volume":"396","author":"Mayer","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"jsc200004r21","first-page":"549","article-title":"Dolutegravir-based antiretroviral therapy for patients coinfected with tuberculosis and human immunodeficiency virus: a multicenter, noncomparative, open-label, randomized trial.","volume":"70","author":"Dooley","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"6","key":"jsc200004r22","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/jac\/dkz068","article-title":"Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide.","volume":"74","author":"Cerrone","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"jsc200004r23","doi-asserted-by":"crossref","first-page":"e401","DOI":"10.1016\/S2352-3018(20)30032-1","article-title":"Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1\/2 trial.","volume":"7","author":"Dooley","year":"2020","journal-title":"Lancet HIV"},{"key":"jsc200004r24","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2019.104543","article-title":"Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine\/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide (D\/C\/F\/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1.","volume":"170","author":"Eron","year":"2019","journal-title":"Antiviral Res"},{"key":"jsc200004r25","article-title":"Efficacy and safety of switching to dolutegravir\/lamivudine fixed-dose two-drug regimen versus continuing a tenofovir alafenamide-based three- or four-drug regimen for maintenance of virologic suppression in adults with HIV-1: phase 3, randomized, non-inferiority TANGO Study.","author":"van Wyk","journal-title":"Clin Infect Dis"},{"issue":"9","key":"jsc200004r26","doi-asserted-by":"crossref","first-page":"e576","DOI":"10.1016\/S2352-3018(19)30149-3","article-title":"Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies.","volume":"6","author":"Aboud","year":"2019","journal-title":"Lancet HIV"},{"issue":"12","key":"jsc200004r27","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","article-title":"Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression.","volume":"382","author":"Swindells","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"jsc200004r28","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa1909512","article-title":"Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection.","volume":"382","author":"Orkin","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"jsc200004r29","first-page":"11","article-title":"Cabotegravir + rilpivirine every 2 months is noninferior to monthly: ATLAS-2M STUDY [Abstract 34] in special issue: Abstracts From the 2020 Conference on Retroviruses and Opportunistic Infections.","volume":"28","author":"Overton","year":"2020","journal-title":"Top Antivir Med"},{"issue":"10","key":"jsc200004r30","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz330","article-title":"Impact of the M184V\/I mutation on the efficacy of abacavir\/lamivudine\/dolutegravir therapy in HIV treatment-experienced patients.","volume":"6","author":"Olearo","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"jsc200004r31","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1093\/jac\/dkz347","article-title":"Switching to bictegravir\/emtricitabine\/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V\/I.","volume":"74","author":"Andreatta","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"jsc200004r32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.02533-18","article-title":"Resistance analysis of bictegravir-emtricitabine-tenofovir alafenamide in HIV-1 treatment-naive patients through 48 weeks.","volume":"63","author":"Acosta","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"jsc200004r33","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1016\/S2352-3018(18)30295-9","article-title":"Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies.","volume":"6","author":"Althoff","year":"2019","journal-title":"Lancet HIV"},{"issue":"4","key":"jsc200004r34","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1093\/infdis\/jiaa125","article-title":"Changes in renal function after switching from TDF to TAF in HIV-infected individuals: a prospective cohort study.","volume":"222","author":"Surial","year":"2020","journal-title":"J Infect Dis"},{"issue":"14","key":"jsc200004r35","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1097\/QAD.0000000000001911","article-title":"Zoledronic acid is superior to tenofovir disoproxil fumarate-switching for low bone mineral density in adults with HIV.","volume":"32","author":"Hoy","year":"2018","journal-title":"AIDS"},{"issue":"10","key":"jsc200004r36","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz414","article-title":"Changes in body mass index and atherosclerotic disease risk score after switching from tenofovir disoproxil fumarate to tenofovir alafenamide.","volume":"6","author":"Schafer","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"jsc200004r39","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S1473-3099(19)30036-2","article-title":"Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial.","volume":"19","author":"Aboud","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"jsc200004r40","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/infdis\/jiz281","article-title":"Long-term outcomes in a large randomized trial of HIV-1 salvage therapy: 96-week results of AIDS Clinical Trials Group A5241 (OPTIONS).","volume":"221","author":"Gandhi","year":"2020","journal-title":"J Infect Dis"},{"issue":"7","key":"jsc200004r41","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa1711460","article-title":"Phase 3 study of ibalizumab for multidrug-resistant HIV-1.","volume":"379","author":"Emu","year":"2018","journal-title":"N Engl J Med"},{"key":"jsc200004r42","doi-asserted-by":"crossref","first-page":"S303","DOI":"10.1093\/ofid\/ofz360.729","article-title":"Ibalizumab efficacy and safety through 48 weeks of treatment: results of an expanded access protocol (TMB-311).","volume":"6","author":"Emu","year":"2020","journal-title":"Cre Open Forum Infect Dis"},{"issue":"2","key":"jsc200004r43","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/QAI.0000000000002241","article-title":"Clinical and economic impact of ibalizumab for people with multidrug-resistant HIV in the United States.","volume":"83","author":"Millham","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"13","key":"jsc200004r44","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1056\/NEJMoa1902493","article-title":"Fostemsavir in adults with multidrug-resistant HIV-1 infection.","volume":"382","author":"Kozal","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"jsc200004r45","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/jac\/dkz553","article-title":"Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy.","volume":"75","author":"Soulie","year":"2020","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"jsc200004r49","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0033354917738769","article-title":"Evaluating the evidence for more frequent than annual HIV screening of gay, bisexual, and other men who have sex with men in the United States: results from a systematic review and CDC expert consultation.","volume":"133","author":"DiNenno","year":"2018","journal-title":"Public Health Rep"},{"issue":"10","key":"jsc200004r50","doi-asserted-by":"crossref","first-page":"e00757","DOI":"10.1128\/JCM.00757-19","article-title":"Decreased seroreactivity in individuals initiating antiretroviral therapy during acute HIV infection.","volume":"57","author":"Manak","year":"2019","journal-title":"J Clin Microbiol"},{"issue":"4","key":"jsc200004r51","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/hiv.12825","article-title":"Post-exposure prophylaxis following consented sexual exposure: impact of national recommendations on user profile, drug regimens and estimates of averted HIV infections.","volume":"21","author":"Pereira","year":"2020","journal-title":"HIV Med"},{"key":"jsc200004r52","article-title":"HIV post-exposure prophylaxis-in-pocket (\u201cPIP\u201d): long-term follow-up of individuals with low-frequency, high-risk HIV exposures.","author":"Alghamdi","journal-title":"AIDS"},{"issue":"7","key":"jsc200004r53","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1093\/cid\/ciz372","article-title":"Clinical impact and cost-effectiveness of genotype testing at human immunodeficiency virus diagnosis in the United States.","volume":"70","author":"Hyle","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"6","key":"jsc200004r54","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1093\/jac\/dkz067","article-title":"Surveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practice.","volume":"74","author":"Alvarez","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"jsc200004r55","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/cid\/ciy463","article-title":"Human immunodeficiency virus drug resistance: 2018 recommendations of the International Antiviral Society-USA Panel.","volume":"68","author":"G\u00fcnthard","year":"2019","journal-title":"Clin Infect Dis"},{"key":"jsc200004r56","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.eclinm.2019.07.001","article-title":"The potential impact of initiating antiretroviral therapy with integrase inhibitors on HIV transmission risk in British Columbia, Canada.","volume":"13","author":"Zhu","year":"2019","journal-title":"EClinicalMedicine"},{"key":"jsc200004r57","first-page":"35s","article-title":"Abundance of penile anaerobes, IL-8, and the risk of HIV acquisition, Rakai, Uganda [Abstract 87] in special issue: Abstracts From the 2017 Conference on Retroviruses and Opportunistic Infections.","volume":"27","author":"Liu","year":"2017","journal-title":"Top Antivir Med"},{"issue":"11","key":"jsc200004r59","doi-asserted-by":"crossref","first-page":"e482","DOI":"10.1016\/S2352-3018(17)30181-9","article-title":"Rapidly declining HIV infection in MSM in central London.","volume":"4","author":"Nwokolo","year":"2017","journal-title":"Lancet HIV"},{"issue":"11","key":"jsc200004r60","doi-asserted-by":"crossref","first-page":"e629","DOI":"10.1016\/S2352-3018(18)30215-7","article-title":"Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study.","volume":"5","author":"Grulich","year":"2018","journal-title":"Lancet HIV"},{"issue":"21","key":"jsc200004r64","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199711203372101","article-title":"A case-control study of HIV seroconversion in health care workers after percutaneous exposure.","volume":"337","author":"Cardo","year":"1997","journal-title":"N Engl J Med"},{"issue":"6","key":"jsc200004r65","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1080\/17425255.2020.1752662","article-title":"Pharmacology and drug interactions with HIV PrEP in transgender persons receiving gender affirming hormone therapy.","volume":"16","author":"Yager","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"11","key":"jsc200004r70","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0207005","article-title":"Global and regional trends of people living with HIV aged 50 and over: estimates and projections for 2000-2020.","volume":"13","author":"Autenrieth","year":"2018","journal-title":"PLoS One"},{"issue":"6","key":"jsc200004r71","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.7954","article-title":"Comparison of overall and comorbidity-free life expectancy between insured adults with and without HIV infection, 2000-2016.","volume":"3","author":"Marcus","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"9","key":"jsc200004r72","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1089\/aid.2011.0377","article-title":"Definition of advanced age in HIV infection: looking for an age cut-off.","volume":"28","author":"Blanco","year":"2012","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"1","key":"jsc200004r73","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12877-018-0789-0","article-title":"The increasing burden and complexity of multi-morbidity and polypharmacy in geriatric HIV patients: a cross sectional study of people aged 65-74 years and more than 75 years.","volume":"18","author":"Guaraldi","year":"2018","journal-title":"BMC Geriatr"},{"issue":"1","key":"jsc200004r74","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/QAD.0000000000002372","article-title":"Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV.","volume":"34","author":"Courlet","year":"2020","journal-title":"AIDS"},{"issue":"2","key":"jsc200004r75","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/COH.0000000000000608","article-title":"Polypharmacy in HIV: recent insights and future directions.","volume":"15","author":"Edelman","year":"2020","journal-title":"Curr Opin HIV AIDS"},{"issue":"6","key":"jsc200004r76","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/infdis\/jiaa010","article-title":"Frailty is associated with mortality and incident comorbidity among middle-aged human immunodeficiency virus (HIV)-positive and HIV-negative participants.","volume":"222","author":"Verheij","year":"2020","journal-title":"J Infect Dis"},{"issue":"10","key":"jsc200004r77","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1097\/QAD.0000000000001829","article-title":"Abdominal obesity, sarcopenia, and osteoporosis are associated with frailty in men living with and without HIV.","volume":"32","author":"Hawkins","year":"2018","journal-title":"AIDS"},{"issue":"2","key":"jsc200004r78","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/QAD.0000000000002047","article-title":"Prevalence and 1-year incidence of frailty among women with and without HIV in the Women\u2019s Interagency HIV Study.","volume":"33","author":"Fatukasi","year":"2019","journal-title":"AIDS"},{"issue":"9","key":"jsc200004r79","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1111\/jgs.16034","article-title":"Geriatric syndromes in older adults living with HIV and cognitive impairment.","volume":"67","author":"Hosaka","year":"2019","journal-title":"J Am Geriatr Soc"},{"issue":"10206","key":"jsc200004r80","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0140-6736(19)31785-4","article-title":"Management of frailty: opportunities, challenges, and future directions.","volume":"394","author":"Dent","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"jsc200004r81","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s12877-017-0623-0","article-title":"Measuring frailty in clinical practice: a comparison of physical frailty assessment methods in a geriatric out-patient clinic.","volume":"17","author":"Pritchard","year":"2017","journal-title":"BMC Geriatr"},{"issue":"12","key":"jsc200004r82","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1093\/cid\/ciz670","article-title":"Increased prevalence of neurocognitive impairment in aging people living with human immunodeficiency virus: the ANRS EP58 HAND 55-70 study.","volume":"70","author":"Makinson","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"9","key":"jsc200004r84","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1111\/jgs.12410","article-title":"Does social isolation predict hospitalization and mortality among HIV+ and uninfected older veterans?","volume":"61","author":"Greysen","year":"2013","journal-title":"J Am Geriatr Soc"},{"key":"jsc200004r86","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ypmed.2017.12.018","article-title":"HIV-related stigma, racial discrimination, and gender discrimination: pathways to physical and mental health-related quality of life among a national cohort of women living with HIV.","volume":"107","author":"Logie","year":"2018","journal-title":"Prev Med"},{"issue":"2","key":"jsc200004r87","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/QAI.0000000000001898","article-title":"HIV-related stigma affects cognition in older men living with HIV.","volume":"80","author":"Lam","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"jsc200004r88","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1001\/jamainternmed.2019.7108","article-title":"HIV antiretroviral therapy costs in the United States, 2012-2018.","volume":"180","author":"McCann","year":"2020","journal-title":"JAMA Intern Med"},{"key":"jsc200004r89","doi-asserted-by":"crossref","first-page":"S339","DOI":"10.1097\/QAI.0000000000002195","article-title":"Cost of differentiated HIV antiretroviral therapy delivery strategies in Sub-Saharan Africa: a systematic review.","volume":"82","author":"Roberts","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"49","key":"jsc200004r90","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.15585\/mmwr.mm6849a1","article-title":"Nonadherence to any prescribed medication due to costs among adults with HIV infection\u2014United States, 2016-2017.","volume":"68","author":"Beer","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"11","key":"jsc200004r91","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1377\/hlthaff.2010.0571","article-title":"Copayment reductions generate greater medication adherence in targeted patients.","volume":"29","author":"Maciejewski","year":"2010","journal-title":"Health Aff (Millwood)"},{"issue":"23","key":"jsc200004r92","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1056\/NEJMp1502020","article-title":"Ending the HIV-AIDS pandemic\u2014follow the science.","volume":"373","author":"Fauci","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"jsc200004r94","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25455","article-title":"What do the Universal Test and Treat trials tell us about the path to HIV epidemic control?","volume":"23","author":"Havlir","year":"2020","journal-title":"J Int AIDS Soc"},{"key":"jsc200004r95","doi-asserted-by":"crossref","first-page":"S213","DOI":"10.1097\/QAD.0000000000002355","article-title":"Global, regional and country-level 90-90-90 estimates for 2018: assessing progress towards the 2020 target.","volume":"33","author":"Marsh","year":"2019","journal-title":"AIDS"},{"issue":"6","key":"jsc200004r96","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/COH.0000000000000592","article-title":"Editorial: can we end HIV as a public health problem globally? progress towards achieving the UNAIDS 90-90-90 goals.","volume":"14","author":"Del Rio","year":"2019","journal-title":"Curr Opin HIV AIDS"},{"issue":"9","key":"jsc200004r97","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1001\/jama.2019.1343","article-title":"Ending the HIV epidemic: a plan for the United States.","volume":"321","author":"Fauci","year":"2019","journal-title":"JAMA"},{"key":"jsc200004r12","author":"Zash","year":"2020"},{"key":"jsc200004r37","author":"Mallon","year":"2020"},{"key":"jsc200004r38","author":"Bajema","year":"2019"},{"key":"jsc200004r62","author":"Landovitz","year":"2020"},{"key":"jsc200004r63","author":"Krakower","year":"2020"},{"key":"jsc200004r83","author":"Harris","year":"2018"},{"key":"jsc200004r85","author":"Nguyen","year":"2019"},{"key":"jsc200004r9","unstructured":"AIDS Info. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. Accessed May 18, 2020. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-opportunistic-infection\/whats-new-guidelines?"},{"key":"jsc200004r46","unstructured":"Sanford Guide. Sanford guide collection. Accessed August 25, 2020. https:\/\/www.sanfordguide.com\/products\/digital-subscriptions\/collection\/?"},{"key":"jsc200004r47","unstructured":"US Centers for Disease and Control and Prevention. Vaccines and immunizations. Accessed September 22, 2020. https:\/\/www.cdc.gov\/vaccines\/index.html"},{"key":"jsc200004r48","unstructured":"US Centers for Disease and Control and Prevention. ACIP vaccine recommendations and guidelines. Accessed August 25, 2020. https:\/\/www.cdc.gov\/vaccines\/hcp\/acip-recs\/index.html"},{"key":"jsc200004r58","unstructured":"Seattle and King County Infectious Disease Asssessment Unit. HIV\/AIDS epidemiology report 2017. Accessed June 12, 2020. https:\/\/www.kingcounty.gov\/depts\/health\/communicable-diseases\/hiv-std\/patients\/epidemiology\/~\/media\/depts\/health\/communicable-diseases\/documents\/hivstd\/2017-hiv-aids-epidemiology-annual-report.ashx"},{"key":"jsc200004r61","unstructured":"World Health Organization. What's the 2+1+1? event-driven oral pre-exposure prophylaxis to prevent HIV for men who have sex with men: update to WHO's recommendation on oral PrEP. Accessed March 22, 2020. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/325955\/WHO-CDS-HIV-19.8-eng.pdf?ua=1"},{"key":"jsc200004r66","unstructured":"AETC National Coordinating Resource Center. National clinician consultation center. Accessed May 16, 2020. https:\/\/aidsetc.org\/aetc-program\/national-clinician-consulation-center?"},{"key":"jsc200004r67","unstructured":"US Centers for Disease and Control and Prevention. HIV surveillance report, 2018 (preliminary). Accessed March 22, 2020. https:\/\/www.cdc.gov\/hiv\/library\/reports\/hiv-surveillance.html"},{"key":"jsc200004r68","unstructured":"UNAIDS. UNAIDS data 2019. Accessed March 22, 2020. http:\/\/aidsinfo.unaids.org\/"},{"key":"jsc200004r69","unstructured":"Swiss HIV Cohort Study. Swiss HIV Cohort Study current status: age distribution of active patients by year, in the SHCS 1992-2018. Accessed August 24, 2020. http:\/\/www.shcs.ch\/232-current-status"},{"key":"jsc200004r93","unstructured":"UNAIDS. Communities at the centre: global AIDS update 2019. Accessed April 16, 2020. https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/2019-global-AIDS-update_en.pdf"},{"key":"jsc200004r98","unstructured":"Infectious Diseases Society of America. COVID-19 resource center. Accessed May 18, 2020. https:\/\/www.idsociety.org\/covid-19-real-time-learning-network\/"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2771873\/jama_saag_2020_sc_200004_1603319721.57892.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T19:26:55Z","timestamp":1617910015000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2771873"}},"subtitle":["2020 Recommendations of the International Antiviral Society\u2013USA Panel"],"short-title":[],"issued":{"date-parts":[[2020,10,27]]},"references-count":98,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2020,10,27]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2020.17025","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10,27]]}}}